Proteostasis and Ribostasis Impairment as Common Cell Death Mechanisms in Neurodegenerative Diseases

키워드

참고문헌 (145)

1. Dugger BN, "Pathology of neurodegenerative diseases", Cold Spring Harb Perspect Biol, 9, pp.a028035~ (2017)
2. Hou Y, "Ageing as a risk factor for neurodegenerative disease", Nat Rev Neurol, 15, pp.565~581 (2019)
3. Zbinden A, "Phase separation and neurodegenerative diseases : a disturbance in the force", Dev Cell, 55, pp.45~68 (2020)
4. Feng Z, "Formation of biological condensates via phase separation : characteristics, analytical methods, and physiological implications", J Biol Chem, 294, pp.14823~14835 (2019)
5. Liao YC, "RNA granules hitchhike on lysosomes for long-distance transport, using annexin A11 as a molecular tether", Cell, 179, pp.147~164 (2019)
6. Nahm M, "ANXA11mutations in ALS cause dysregulation of calcium homeostasis and stress granule dynamics", Sci Transl Med, 12, pp.eaax3993~ (2020)
7. Vahsen BF, "Non-neuronal cells in amyotrophic lateral sclerosis-from pathogenesis to biomarkers", Nat Rev Neurol, 17, pp.333~348 (2021)
8. Balch WE, "Adapting proteostasis for disease intervention", Science, 319, pp.916~919 (2008)
9. Labbadia J, "The biology of proteostasis in aging and disease", Annu Rev Biochem, 84, pp.435~464 (2015)
10. Kim YE, "Molecular chaperone functions in protein folding and proteostasis", Annu Rev Biochem, 82, pp.323~355 (2013)
11. Dai C, "HSF1 : guardian of proteostasis in cancer", Trends Cell Biol, 26, pp.17~28 (2016)
12. Li J, "Rethinking HSF1 in stress, development, and organismal health", Trends Cell Biol, 27, pp.895~905 (2017)
13. Anckar J, "Regulation of HSF1 function in the heat stress response : implications in aging and disease", Annu Rev Biochem, 80, pp.1089~1115 (2011)
14. Zheng X, "Dynamic control of Hsf1 during heat shock by a chaperone switch and phosphorylation", Elife, 5, pp.e18638~ (2016)
15. Zou J, "Repression of heat shock transcription factor HSF1 activation by HSP90(HSP90complex)that forms a stress-sensitive complex with HSF1", Cell, 94, pp.471~480 (1998)
16. Pickart CM, "Mechanisms underlying ubiquitination", Annu Rev Biochem, 70, pp.503~533 (2001)
17. Baumeister W, "The proteasome : paradigm of a self-compartmentalizing protease", Cell, 92, pp.367~380 (1998)
18. Ciechanover A, "Proteolysis : from the lysosome to ubiquitin and the proteasome", Nat Rev Mol Cell Biol, 6, pp.79~87 (2005)
19. Murata S, "CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein", EMBO Rep, 2, pp.1133~1138 (2001)
20. Esser C, "Cooperation of molecular chaperones with the ubiquitin", proteasome system, 2004, pp.1695, 171~188
21. Mizushima N, "Autophagy : process and function", Genes Dev, 21, pp.2861~2873 (2007)
22. Klionsky DJ, "Vacuolar import of proteins and organelles from the cytoplasm", Annu Rev Cell Dev Biol, 15, pp.1~32 (1999)
23. Cuervo AM, "Autophagy : in sickness and in health", Trends Cell Biol, 14, pp.70~77 (2004)
24. Majeski AE, "Mechanisms of chaperone-mediated autophagy", Int J Biochem Cell Biol, 36, pp.2435~2444 (2004)
25. Seonghee Jung, "Autophagy as a decisive process for cell death", Experimental and Molecular Medicine, 52, pp.1~10 (2020), 생화학분자생물학회[DOI]
26. Yonekawa T, "Autophagy and cell death", Essays Biochem, 55, pp.105~117 (2013)
27. Johansen T, "Selective autophagy mediated by autophagic adapter proteins", Autophagy, 7, pp.279~296 (2011)
28. Eskelinen EL, "Autophagy : a lysosomal degradation pathway with a central role in health and disease", Biochim Biophys Acta, 1793, pp.664~673 (2009)
29. Cuervo AM, "Chaperone-mediated autophagy : roles in disease and aging", Cell Res, 24, pp.92~104 (2014)
30. Dice JF, "Chaperone-mediated autophagy", Autophagy, 3, pp.295~299 (2007)
31. Rubinsztein DC, "Autophagy and aging", Cell, 146, pp.682~695 (2011)
32. Hipp MS, "The proteostasis network and its decline in ageing", Nat Rev Mol Cell Biol, 20, pp.421~435 (2019)
33. Brannan KW, "SONAR discovers RNA-binding proteins from analysis of large-scale protein-protein interactomes", Mol Cell, 64, pp.282~293 (2016)
34. Schieweck R, "RNA-binding proteins balance brain function in health and disease", Physiol Rev, 101, pp.1309~1370 (2021)
35. Bryant CD, "RNA-binding proteins, neural development and the addictions", Genes Brain Behav, 15, pp.169~186 (2016)
36. Kiebler MA, "Neuronal RNA granules : movers and makers", Neuron, 51, pp.685~690 (2006)
37. Yang P, "G3BP1 is a tunable switch that triggers phase separation to assemble stress granules", Cell, 181, pp.325~345 (2020)
38. Alami NH, "Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations", Neuron, 81, pp.536~543 (2014)
39. Scheltens P, "Alzheimer’s disease", Lancet, 397, pp.1577~1590 (2021)
40. Takano M, "Proteomic analysis of the hippocampus in Alzheimer’s disease model mice by using two-dimensional fluorescence difference in gel electrophoresis", Neurosci Lett, 534, pp.85~89 (2013)
41. Magrané J, "Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons", J Neurosci, 24, pp.1700~1706 (2004)
42. Evans CG, "Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42)aggregation in vitro", J Biol Chem, 281, pp.33182~33191 (2006)
43. Hoshino T, "Suppression of Alzheimer’s disease-related phenotypes by expression of heat shock protein 70 in mice", J Neurosci, 31, pp.5225~5234 (2011)
44. Wang H, "ATP impedes the inhibitory effect of Hsp90 on Aβ40 fibrillation", J Mol Biol, 433, pp.166717~ (2021)
45. Yu WH, "Macroautophagy--a novel beta-amyloid peptide-generating pathway activated in Alzheimer’s disease", J Cell Biol, 171, pp.87~98 (2005)
46. Yu WH, "Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities : implications for beta-amyloid peptide over-production and localization in Alzheimer’s disease", Int J Biochem Cell Biol, 36, pp.2531~2540 (2004)
47. Nixon RA, "Extensive involvement of autophagy in Alzheimer disease : an immuno-electron microscopy study", J Neuropathol Exp Neurol, 64, pp.113~122 (2005)
48. Sanchez-Varo R, "Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer’s mice hippocampus", Acta Neuropathol, 123, pp.53~70 (2012)
49. Yang DS, "Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer’s disease ameliorates amyloid pathologies and memory deficits", Brain, 134(Pt 1), pp.258~277 (2011)
50. Shimura H, "CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival", J Biol Chem, 279, pp.4869~4876 (2004)
51. Luo W, "Roles of heatshock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies", Proc Natl Acad Sci U S A, 104, pp.9511~9516 (2007)
52. Lackie RE, "The Hsp70", Hsp90 chaperone machinery in neurodegenerative diseases, 2017, pp.11, 254~
53. Basso AD, "Akt forms an intracellular complex with heat shock protein 90(Hsp90)and Cdc37 and is destabilized by inhibitors of Hsp90 function", J Biol Chem, 277, pp.39858~39866 (2002)
54. Lee KY, "Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain", Neurosci Res, 34, pp.21~29 (1999)
55. Stanford PM, "Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia", Brain, 126(Pt 4), pp.814~826 (2003)
56. Woollacott IO, "The clinical spectrum of sporadic and familial forms of frontotemporal dementia", J Neurochem, 138(Suppl 1), pp.6~31 (2016)
57. Ginsberg SD, "Sequestration of RNA in Alzheimer’s disease neurofibrillary tangles and senile plaques", Ann Neurol, 41, pp.200~209 (1997)
58. Lester E, "Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components", Neuron, 109, pp.1675~1691 (2021)
59. Kanaan NM, "Liquid-liquid phase separation induces pathogenic tau conformations in vitro", Nat Commun, 11, pp.2809~ (2020)
60. Atlas R, "The insulin-like growth factor mRNA binding-protein IMP-1 and the Ras-regulatory protein G3BP associate with tau mRNA and HuD protein in differentiated P19 neuronal cells", J Neurochem, 89, pp.613~626 (2004)
61. Maziuk BF, "RNA binding proteins co-localize with small tau inclusions in tauopathy", Acta Neuropathol Commun, 6, pp.71~ (2018)
62. Vanderweyde T, "Interaction of tau with the RNA-binding protein TIA1 regulates tau pathophysiology and toxicity", Cell Rep, 15, pp.1455~1466 (2016)
63. Kalia LV, "Parkinson’s disease", Lancet, 386, pp.896~912 (2015)
64. Spillantini MG, "Alpha-synuclein in Lewy bodies", Nature, 388, pp.839~840 (1997)
65. Gibb WR, "The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease", J Neurol Neurosurg Psychiatry, 51, pp.745~752 (1988)
66. McLean PJ, "TorsinA and heat shock proteins act as molecular chaperones : suppression of alpha-synuclein aggregation", J Neurochem, 83, pp.846~854 (2002)
67. Kuzuhara S, "Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study", Acta Neuropathol, 75, pp.345~353 (1988)
68. Shin Y, "The cochaperone carboxyl terminus of Hsp70-interacting protein(CHIP)mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways", J Biol Chem, 280, pp.23727~23734 (2005)
69. Kitada T, "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism", Nature, 392, pp.605~608 (1998)
70. Um JW, "Parkin directly modulates 26S proteasome activity", J Neurosci, 30, pp.11805~11814 (2010)
71. Leroy E, "The ubiquitin pathway in Parkinson’s disease", Nature, 395, pp.451~452 (1998)
72. Dehay B, "Pathogenic lysosomal depletion in Parkinson’s disease", J Neurosci, 30, pp.12535~12544 (2010)
73. Tanji K, "Alteration of autophagosomal proteins(LC3, GABARAP and GATE-16)in Lewy body disease", Neurobiol Dis, 43, pp.690~697 (2011)
74. Crews L, "Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy", PLoS One, 5, pp.e9313~ (2010)
75. Higashi S, "Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies", J Neuropathol Exp Neurol, 70, pp.264~280 (2011)
76. Klucken J, "Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway", Autophagy, 8, pp.754~766 (2012)
77. Chu Y, "Alterations in lysosomal and proteasomal markers in Parkinson’s disease : relationship to alpha-synuclein inclusions", Neurobiol Dis, 35, pp.385~398 (2009)
78. Alvarez-Erviti L, "Chaperone-mediated autophagy markers in Parkinson disease brains", Arch Neurol, 67, pp.1464~1472 (2010)
79. Orenstein SJ, "Interplay of LRRK2 with chaperone-mediated autophagy", Nat Neurosci, 16, pp.394~406 (2013)
80. Plowey ED, "Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SHSY5Y cells", J Neurochem, 105, pp.1048~1056 (2008)
81. Bento CF, "The Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway", Nat Commun, 7, pp.11803~ (2016)
82. Gan-Or Z, "Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease", Autophagy, 11, pp.1443~1457 (2015)
83. Sidransky E, "Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease", N Engl J Med, 361, pp.1651~1661 (2009)
84. Vilariño-Güell C, "VPS35 mutations in Parkinson disease", Am J Hum Genet, 89, pp.162~167 (2011)
85. Zimprich A, "A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease", Am J Hum Genet, 89, pp.168~175 (2011)
86. Pickrell AM, "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease", Neuron, 85, pp.257~273 (2015)
87. Kisos H, "Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathies", PLoS One, 7, pp.e46817~ (2012)
88. Schaser AJ, "Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders", Sci Rep, 9, pp.10919~ (2019)
89. Sawner AS, "Modulating α-synuclein liquid-liquid phase separation", Biochemistry, 60, pp.3676~3696 (2021)
90. Brown RH, "Amyotrophic lateral sclerosis", N Engl J Med, 377, pp.162~172 (2017)
91. Ling SC, "Converging mechanisms in ALS and FTD : disrupted RNA and protein homeostasis", Neuron, 79, pp.416~438 (2013)
92. Fecto F, "SQSTM1mutations in familial and sporadic amyotrophic lateral sclerosis", Arch Neurol, 68, pp.1440~1446 (2011)
93. Li C, "Optineurin mutations in patients with sporadic amyotrophic lateral sclerosis in China", Amyotroph Lateral Scler Frontotemporal Degener, 16, pp.485~489 (2015)
94. Deng HX, "Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS", dementia, 2011, pp.477, 211~215
95. Johnson JO, "Exome sequencing reveals VCP mutations as a cause of familial ALS", Neuron, 68, pp.857~864 (2010)
96. Freischmidt A, "Haploinsufficiency of TBK1 causes familial ALS and frontotemporal dementia", Nat Neurosci, 18, pp.631~636 (2015)
97. Cirulli ET, "Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways", Science, 347, pp.1436~1441 (2015)
98. Teyssou E, "Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis : genetics and neuropathology", Acta Neuropathol, 125, pp.511~522 (2013)
99. Ito H, "Clinicopathologic study on an ALS family with a heterozygous E478G optineurin mutation", Acta Neuropathol, 122, pp.223~229 (2011)
100. Wild P, "Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth", Science, 333, pp.228~233 (2011)
101. Pilli M, "TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation", Immunity, 37, pp.223~234 (2012)
102. Rothenberg C, "Ubiquilin at a crossroads in protein degradation pathways", Autophagy, 6, pp.979~980 (2010)
103. Williams KL, "UBQLN2", ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis, 2012, pp.33, 2527~
104. Rosen DR, "Mutations in Cu", Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, 1993, pp.362, 59~62
105. Prudencio M, "Variation in aggregation propensities among ALS-associated variants of SOD1 : correlation to human disease", Hum Mol Genet, 18, pp.3217~3226 (2009)
106. Valentine JS, "Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis", Annu Rev Biochem, 74, pp.563~593 (2005)
107. Forsberg K, "Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS", FTD-associated genes, 2019, pp.90, 861~869
108. Watanabe M, "Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues", Neurobiol Dis, 8, pp.933~941 (2001)
109. Weisberg SJ, "Compartmentalization of superoxide dismutase 1(SOD1G93A)aggregates determines their toxicity", Proc Natl Acad Sci U S A, 109, pp.15811~15816 (2012)
110. Kabuta T, "Degradation of amyotrophic lateral sclerosis-linked mutant Cu, Zn-superoxide dismutase proteins by macroautophagy and the proteasome", J Biol Chem, 281, pp.30524~30533 (2006)
111. Cheroni C, "Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis", Hum Mol Genet, 18, pp.82~96 (2009)
112. Zhang F, "Interaction between familial amyotrophic lateral sclerosis(ALS)-linked SOD1 mutants and the dynein complex", J Biol Chem, 282, pp.16691~16699 (2007)
113. Arai T, "TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis", Biochem Biophys Res Commun, 351, pp.602~611 (2006)
114. Neumann M, "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis", Science, 314, pp.130~133 (2006)
115. Brown RH Jr, "Amyotrophic lateral sclerosis", N Engl J Med, 377, pp.1602~ (2017)
116. Wolozin B, "Regulated protein aggregation : stress granules and neurodegeneration", Mol Neurodegener, 7, pp.56~ (2012)
117. Gopal PP, "Amyotrophic lateral sclerosis-linked mutations increase the viscosity of liquid-like TDP-43 RNP granules in neurons", Proc Natl Acad Sci U S A, 114, pp.E2466~E2475 (2017)
118. Dang M, "ALS-causing D169G mutation disrupts the ATPbinding capacity of TDP-43 RRM1 domain", Biochem Biophys Res Commun, 524, pp.459~464 (2020)
119. Hasegawa M, "Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis", Ann Neurol, 64, pp.60~70 (2008)
120. Nonaka T, "Phosphorylation of TAR DNA-binding protein of 43 kDa(TDP-43)by truncated casein kinase 1δ triggers mislocalization and accumulation of TDP-43", J Biol Chem, 291, pp.5473~5483 (2016)
121. Boyd JD, "A high-content screen identifies novel compounds that inhibit stressinduced TDP-43 cellular aggregation and associated cytotoxicity", J Biomol Screen, 19, pp.44~56 (2014)
122. Liachko NF, "CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration", Ann Neurol, 74, pp.39~52 (2013)
123. Martínez-González L, "Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment", Sci Rep, 10, pp.4449~ (2020)
124. Wang P, "Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program", Nat Commun, 8, pp.82~ (2017)
125. Elden AC, "Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS", Nature, 466, pp.1069~1075 (2010)
126. Becker LA, "Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice", Nature, 544, pp.367~371 (2017)
127. Mackenzie IRA, "Fused in sarcoma neuropathology in neurodegenerative disease", Cold Spring Harb Perspect Med, 7, pp.a024299~ (2017)
128. Kim HJ, "Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1cause multisystem proteinopathy and ALS", Nature, 495, pp.467~473 (2013)
129. Martinez FJ, "Protein-RNA networks regulated by normal and ALS-associated mutant HNRNPA2B1 in the nervous system", Neuron, 92, pp.780~795 (2016)
130. Doble A, "The pharmacology and mechanism of action of riluzole", Neurology, 47(6 Suppl 4), pp.S233~S241 (1996)
131. Bensimon G, "A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS", Riluzole Study Group, 1994, pp.330, 585~591
132. Cacabelos R, "Donepezil in Alzheimer’s disease : from conventional trials to pharmacogenetics", Neuropsychiatr Dis Treat, 3, pp.303~333 (2007)
133. 김승현, "A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation", Dementia and Neurocognitive Disorders(대한치매학회지), 18(2), pp.33~46 (2019), 대한치매학회[DOI]
134. Winklhofer KF, "The two faces of protein misfolding : gain-and loss-of-function in neurodegenerative diseases", EMBO J, 27, pp.336~349 (2008)
135. Malik I, "Molecular mechanisms underlying nucleotide repeat expansion disorders", Nat Rev Mol Cell Biol, 22, pp.589~607 (2021)
136. Vashist S, "Applying Hsp104 to protein-misfolding disorders", Biochem Cell Biol, 88, pp.1~13 (2010)
137. Lo Bianco C, "Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease", J Clin Invest, 118, pp.3087~3097 (2008)
138. Jackrel ME, "Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events", Cell, 156, pp.170~182 (2014)
139. Jackrel ME, "Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins", Dis Model Mech, 7, pp.1175~1184 (2014)
140. Walters RW, "Coupling of ribostasis and proteostasis : Hsp70 proteins in mRNA metabolism", Trends Biochem Sci, 40, pp.552~559 (2015)
141. Fare CM, "(Dis)solving the problem of aberrant protein states", Dis Model Mech, 14, pp.dmm048983~ (2021)
142. Yu H, "HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells", Science, 371, pp.eabb4309~ (2021)
143. Gu J, "Hsp40 proteins phase separate to chaperone the assembly and maintenance of membraneless organelles", Proc Natl Acad Sci U S A, 117, pp.31123~31133 (2020)
144. Guo L, "Nuclear-import receptors reverse aberrant phase transitions of RNAbinding proteins with prion-like domains", Cell, 173, pp.677~692 (2018)
145. Mann JR, "RNA binding antagonizes neurotoxic phase transitions of TDP-43", Neuron, 102, pp.321~338 (2019)

관련 논문AI추천